Combination therapy offers improved visual outcome compared with anti-VEGF monotherapy, trial finds

“Use of a novel anti-platelet-derived growth factor therapy in concert with ranibizumab resulted in a statistically significant improvement in visual outcome vs. ranibizumab monotherapy for the treatment of wet age-related macular degeneration, according to a press release from Ophthotech…”

Retinal Consultants of AZ is committed to clinical research and the pursuit of new and improved therapies for retinal diseases. Our Retinal Research Institute is proud to be intimately involved with this groundbreaking study. We helped to coordinate the study design, data collection, and were enthusiastically involved with study recruitment. In fact, we were the highest recruiters in the entire study. We would like to thank our referring doctors for helping to make this achievement possible. Without your help, we would not be able to contribute to this innovative clinical trial.

Read the rest of this article by Healio: Ocular Surgery News

Posted in: Uncategorized